公开(公告)号：US20170211089A1

公开(公告)日：2017-07-27

申请号：US15348419

申请日：2016-11-10

Applicant: CARNEGIE INSTITUTION OF WASHINGTON

Inventor： Wolf B. FROMMER ,  Sylvie LALONDE

IPC: C12N15/82

CPC classification number: C12N15/8279 ,  C07K14/415 ,  C07K14/43545 ,  C07K14/47 ,  C12N15/8218 ,  C12N15/8245 ,  C12N15/8246

Abstract: A novel class of transporter protein, referred to as SWEET, GLUE or Glü, is disclosed. These transporters provide a novel system for the transportation of sugars across membranes within a cell and between the inside and outside of a cell. Such transporters are useful for understanding and altering the sugar concentration within certain organs of an organism, and within certain organelles within the cell. These transporters are also useful in protecting plants from a pathogen attack.

公开(公告)号：US09562081B2

公开(公告)日：2017-02-07

申请号：US12773500

申请日：2010-05-04

Applicant: Wolf B. Frommer ,  Sylvie Lalonde

Inventor： Wolf B. Frommer ,  Sylvie Lalonde

IPC: C12N15/113 ,  C12N15/82 ,  C07K14/47 ,  C07K14/415 ,  C07K14/435

CPC classification number: C12N15/8279 ,  C07K14/415 ,  C07K14/43545 ,  C07K14/47 ,  C12N15/8218 ,  C12N15/8245 ,  C12N15/8246

Abstract: A novel class of transporter protein, referred to as SWEET, GLUE or Glü, is disclosed. These transporters provide a novel system for the transportation of sugars across membranes within a cell and between the inside and outside of a cell. Such transporters are useful for understanding and altering the sugar concentration within certain organs of an organism, and within certain organelles within the cell. These transporters are also useful in protecting plants from a pathogen attack.

Abstract translation: 公开了一类新颖的转运蛋白，称为SWEET，GLUE或Glü。 这些转运蛋白提供了一种用于在细胞内和细胞内部和外部的膜之间运输糖的新型系统。 这样的转运蛋白可用于理解和改变生物体的某些器官内和细胞内的某些细胞器内的糖浓度。 这些转运蛋白也可用于保护植物免受病原体攻击。

公开(公告)号：US20130336939A1

公开(公告)日：2013-12-19

申请号：US13982996

申请日：2012-01-31

Applicant: Benjamin Podbilewicz ,  Ori Avinoam ,  Judith M. White

Inventor： Benjamin Podbilewicz ,  Ori Avinoam ,  Judith M. White

IPC: A61K36/00 ,  A61K35/76 ,  A61K35/12 ,  A01N63/00 ,  A61K35/56

CPC classification number: A01N63/00 ,  A61K35/12 ,  A61K35/57 ,  A61K35/76 ,  A61K36/00 ,  A61K38/1767 ,  A61K48/00 ,  C07K14/4354 ,  C07K14/43545 ,  C07K2319/00 ,  C12N15/02 ,  C12N15/86 ,  Y02A50/421

Abstract: There are provided methods and compositions useful in cell-cell fusion using Fusion Family (FF) proteins of nematode origin. There are further provided antinematodal methods and compositions, utilizing fusogenic proteins of the nematode Fusion Family.

Abstract translation: 提供了使用线虫来源的融合家族（FF）蛋白质在细胞融合中有用的方法和组合物。 进一步提供抗线虫方法和组合物，利用线虫融合家族的融合蛋白。

公开(公告)号：US08404631B2

公开(公告)日：2013-03-26

申请号：US12302002

申请日：2007-05-21

Applicant: Stephen P. L. Cary ,  Elizabeth M. Boon ,  Emily Weinert ,  Jonathan A. Winger ,  Michael A. Marletta

Inventor： Stephen P. L. Cary ,  Elizabeth M. Boon ,  Emily Weinert ,  Jonathan A. Winger ,  Michael A. Marletta

IPC: C07K14/00

CPC classification number: C07K14/47 ,  A61K38/00 ,  C07K14/195 ,  C07K14/33 ,  C07K14/435 ,  C07K14/43545 ,  C07K14/43563 ,  C07K14/43581 ,  Y02A50/469 ,  Y02A50/471 ,  Y02A50/478 ,  Y10T436/102499

Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.

Abstract translation: H-NOX蛋白被突变以表现出改善的或最佳的动力学和热力学性质用于血液中氧气输送。 工程化的H-NOX蛋白质包含相对于相应的野生型H-NOX结构域赋予改变的O 2或NO配体结合的突变，并且作为生理上相容的哺乳动物血液氧气载体起作用。 本发明还提供了使用野生型或突变型H-NOX蛋白质治疗任何有利于O 2递送的条件的药物组合物，试剂盒和方法。

公开(公告)号：US20120172413A1

公开(公告)日：2012-07-05

申请号：US13380724

申请日：2010-06-28

Applicant: Andrew Dillin ,  William Mair ,  Ianessa Morantte ,  Reuben Shaw

Inventor： Andrew Dillin ,  William Mair ,  Ianessa Morantte ,  Reuben Shaw

IPC: A01K67/033 ,  A61K31/7052 ,  C12N15/12 ,  G01N33/00

CPC classification number: C07K14/43545 ,  G01N33/5085 ,  G01N2333/912

Abstract: The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to CRTC modulation. In certain embodiments, the invention provides compositions and methods for enhancing longevity in an organism by inhibiting CRTC activity, such as, for example, inhibiting CRTC expression or cellular localization in the organism.

Abstract translation: 本发明涉及长寿增强领域。 更具体地说，本发明提供了与CRTC调节相关的组合物和方法。 在某些实施方案中，本发明提供了通过抑制CRTC活性（例如抑制生物体中的CRTC表达或细胞定位）来增强生物体寿命的组合物和方法。

公开(公告)号：US07732182B2

公开(公告)日：2010-06-08

申请号：US12150094

申请日：2008-04-24

Applicant: Rachel E. Meyers ,  Mark J. Williamson

Inventor： Rachel E. Meyers ,  Mark J. Williamson

IPC: C12N9/12 ,  C12N15/54 ,  C12N15/62 ,  C12N15/74 ,  C12N15/79 ,  C12N15/85

CPC classification number: C07K14/705 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/395 ,  C07K14/43545 ,  C07K14/43581 ,  C07K14/43595 ,  C07K14/463 ,  C07K14/465 ,  C07K14/47 ,  C07K2319/00 ,  C12N9/00 ,  C12N9/0071 ,  C12N9/0083 ,  C12N9/1205 ,  C12N9/18 ,  C12N9/20 ,  C12N9/88 ,  C12N2310/3513 ,  C12Y207/01001 ,  C12Y301/04003

Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供分离的核酸分子，命名为25869,25934,26335,50516,21117,38692,46508,16816,16839,49937,49931和49933核酸分子。 本发明还提供反义核酸分子，包含25869,25934,26335,50521,21117,38692,46508,16816,16839,4467,49931或49933核酸分子的重组表达载体，已经引入了表达载体的宿主细胞 ，以及引入或破坏25869,25934,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933基因的非人类转基因动物。 本发明还进一步提供了分离的25869,2593,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933蛋白，融合蛋白，抗原肽和抗-25869,25934,26335,50365,211117,38692 ，46508,16816,16839,49937,49931或49933抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20090053196A1

公开(公告)日：2009-02-26

申请号：US11632186

申请日：2005-07-29

Applicant: Ralf Baumeister ,  Thorsten Hoppe ,  Britta Spanier ,  Hanns Lochmuller ,  Rolf Stucka

Inventor： Ralf Baumeister ,  Thorsten Hoppe ,  Britta Spanier ,  Hanns Lochmuller ,  Rolf Stucka

IPC: A61K31/70 ,  A01K67/00 ,  A61K38/00 ,  A61K39/395 ,  C12Q1/20

CPC classification number: C12Q1/25 ,  A01K67/0339 ,  A01K2217/075 ,  A01K2227/706 ,  A01K2267/0306 ,  A61K38/00 ,  C07K14/43545 ,  C07K14/4703 ,  C07K14/4707 ,  C12N15/113 ,  C12N15/8509 ,  C12N2310/14 ,  G01N33/573 ,  G01N2333/9015 ,  G01N2500/00 ,  G01N2800/10

Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor/negative regulator/antagonist of the mammalian ortholog of Caenorhabditis elegans CHN-1 and/or of the human CHIP (carboxyl-terminus of Hsc70 interacting protein). Furthermore, the use of said inhibitor/negative regulator/antagonist in medical and pharmaceutical settings is described. In addition, screening methods and tools for the identification of CHIP/CHN-1 inhibitors/antagonists are provided.

Abstract translation: 本发明涉及含有秀丽隐杆线虫CHN-1和/或人CHIP（Hsc70相互作用蛋白的羧基末端）的哺乳动物直系同源物的抑制剂/阴性调节剂/拮抗剂的药物组合物。 此外，描述了在医疗和药物设置中使用所述抑制剂/阴性调节剂/拮抗剂。 此外，还提供了用于鉴定CHIP / CHN-1抑制剂/拮抗剂的筛选方法和工具。

公开(公告)号：US20080141385A1

公开(公告)日：2008-06-12

申请号：US10560563

申请日：2004-06-14

Applicant: T. Keith Blackwell ,  Jae Hyung An

Inventor： T. Keith Blackwell ,  Jae Hyung An

IPC: A01K67/033 ,  C12Q1/68 ,  C12N15/63 ,  C12N5/06 ,  C07K14/00 ,  C12N15/62

CPC classification number: C07K14/43545 ,  C07K2319/60 ,  G01N33/5085

Abstract: The present invention relates, in part, to the C. elegans SKN-1 gene and protein (a transcription factor), and target genes thereof. The invention includes various therapeutic methods and screening methods for identifying antioxidants.

Abstract translation: 本发明部分涉及秀丽隐杆线虫SKN-1基因和蛋白质（转录因子）及其靶基因。 本发明包括用于鉴定抗氧化剂的各种治疗方法和筛选方法。

公开(公告)号：US07368248B2

公开(公告)日：2008-05-06

申请号：US10415657

申请日：2001-11-09

Applicant: Christophe Echeverri ,  Pierre Goenczy ,  Anthony Hyman ,  Steven Jones ,  Karen Oegema ,  Matthew Kirkham

Inventor： Christophe Echeverri ,  Pierre Goenczy ,  Anthony Hyman ,  Steven Jones ,  Karen Oegema ,  Matthew Kirkham

IPC: G01N33/53

CPC classification number: C07K14/43545 ,  A61K38/00

Abstract: The present invention relates to the significant functional role of several C. elegans genes and of their corresponding gene products in cell division and proliferation processes that could be identified by means of RNA-medicated interference (RNAi) and to the identification and isolation of functional orthologues of said genes including all biologically-active derivatives thereof. The invention further relates to the use of said gene products (including said orthologues) in the development or isolation of anti-proliferative agents, particularly their use in appropriate screening assays, and their use for diagnosis and treatment of proliferative diseases.

Abstract translation: 本发明涉及几种秀丽隐杆线虫基因及其相应基因产物在细胞分裂和增殖过程中的重要功能作用，可以通过RNA药物干扰（RNAi）和识别和分离功能性直向同源物 的所述基因，包括其所有生物活性衍生物。 本发明还涉及所述基因产物（包括所述直系同源物）在抗增殖剂的开发或分离中的用途，特别是其在适当的筛选测定中的用途，以及它们在增殖性疾病的诊断和治疗中的应用。

公开(公告)号：US20060162002A1

公开(公告)日：2006-07-20

申请号：US11282262

申请日：2005-11-18

Applicant: Cynthia Kenyon ,  Javier Apfeld ,  Andrew Dillin ,  Delia Garigan ,  Ao-Lin Hsu ,  Josh Lehrer-Graiwer ,  Coleen Murphy

Inventor： Cynthia Kenyon ,  Javier Apfeld ,  Andrew Dillin ,  Delia Garigan ,  Ao-Lin Hsu ,  Josh Lehrer-Graiwer ,  Coleen Murphy

IPC: A01K67/033 ,  C12Q1/68 ,  G01N33/53

CPC classification number: C12N15/111 ,  A01K67/0336 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/43545 ,  C12N2310/14 ,  C12N2320/12 ,  C12N2330/31 ,  C12Q1/26 ,  C12Q1/32 ,  C12Q1/34 ,  C12Q1/527 ,  C12Q1/533 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N2500/10

Abstract: The present invention relates to regulation of adult lifespan in eukaryotes. More particularly, the present invention is directed to methods of assaying for genes, gene products, and genes in pathways controlled by such genes and gene products, using RNAi and microarray analysis, that regulate lifespan (e.g., extend or truncate adult lifespan) in eukaryotes such as invertebrates (e.g., C. elegans), plants, and mammals, e.g., humans. For example, the present invention is directed to genes encoding components of the mitochondrial respiratory chain and genes encoding glycolysis enzymes, which are involved in lifespan regulation, and genes and gene products in pathways controlled by such genes. Other genes and gene products identified as regulating aging and aging pathways include a gene encoding a GTPase; a transcriptional activator; novel genes: llw-1, llw-2, llw-3, and llw-4; genes encoding cytochrome P450 proteins (involved in steroid biosynthesis); a melatonin synthesis gene; genes encoding insulin and insulin-like peptides; genes encoding heat shock factors; genes encoding catalases; stress-response genes; and metabolic genes. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, antisense nucleic acids, and ribozymes, that regulate, e.g., enhance, adult lifespan via modulation of aging associated proteins; as well as to the use of expression profiles, markers, and compositions in diagnosis and therapy related to lifespan extension, life expectancy, and aging. The present invention also relates to gene therapy involving lifespan associated genes.